Therapeutic potential of opioid receptor heteromers in chronic pain and associated comorbidities.
GPCR
drug discovery/target validation
heteromers
ligands
neuropharmacology
opioids
pain
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
revised:
07
06
2021
received:
28
02
2021
accepted:
21
07
2021
pubmed:
10
12
2021
medline:
4
3
2023
entrez:
9
12
2021
Statut:
ppublish
Résumé
Chronic pain affects 20% to 45% of the global population and is often associated with the development of anxio-depressive disorders. Treatment of this debilitating condition remains particularly challenging with opioids prescribed to alleviate moderate to severe pain. However, despite strong antinociceptive properties, numerous adverse effects limit opioid use in the clinic. Moreover, opioid misuse and abuse have become a major health concern worldwide. This prompted efforts to design original strategies that would efficiently and safely relieve pain. Targeting of opioid receptor heteromers is one of these. This review summarizes our current knowledge on the role of heteromers involving opioid receptors in the context of chronic pain and anxio-depressive comorbidities. It also examines how heteromerization in native tissue affects ligand binding, receptor signalling and trafficking properties. Finally, the therapeutic potential of ligands designed to specifically target opioid receptor heteromers is considered. LINKED ARTICLES: This article is part of a themed issue on Advances in Opioid Pharmacology at the Time of the Opioid Epidemic. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v180.7/issuetoc.
Substances chimiques
Analgesics, Opioid
0
Receptors, Opioid
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
994-1013Subventions
Organisme : Centre National de la Recherche Scientifique
Organisme : EURIDOL Graduate school of Pain
ID : school of excellence, PIA, ANR-17-EURE-0022
Organisme : Université de Strasbourg
Informations de copyright
© 2021 The British Pharmacological Society.
Références
Aceto, M. D., Harris, L. S., Negus, S. S., Banks, M. L., Hughes, L. D., Akgun, E., & Portoghese, P. S. (2012). MDAN-21: A bivalent opioid ligand containing mu-agonist and delta-antagonist pharmacophores and its effects in rhesus monkeys. International Journal of Medicinal Chemistry, 2012, 327257. https://doi.org/10.1155/2012/327257
Aguila, B., Coulbault, L., Boulouard, M., Leveille, F., Davis, A., Toth, G., Borsodi, A., Balboni, G., Salvadori, S., Jauzac, P., & Allouche, S. (2007). In vitro and in vivo pharmacological profile of UFP-512, a novel selective delta-opioid receptor agonist; correlations between desensitization and tolerance. British Journal of Pharmacology, 152, 1312-1324. https://doi.org/10.1038/sj.bjp.0707497
Akgun, E., Javed, M. I., Lunzer, M. M., Powers, M. D., Sham, Y. Y., Watanabe, Y., & Portoghese, P. S. (2015). Inhibition of inflammatory and neuropathic pain by targeting a mu opioid receptor/chemokine receptor5 heteromer (MOR-CCR5). Journal of Medicinal Chemistry, 58, 8647-8657. https://doi.org/10.1021/acs.jmedchem.5b01245
Akgun, E., Lunzer, M. M., & Portoghese, P. S. (2019). Combined glia inhibition and opioid receptor agonism afford highly potent analgesics without tolerance. ACS Chemical Neuroscience, 10, 2004-2011. https://doi.org/10.1021/acs.biochem.0c00498
Alexander, S. P., Christopoulos, A., Davenport, A. P., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Southan, C., Davies, J. A., Abbracchio, M. P., Alexander, W., Al-hosaini, K., Bäck, M., Barnes, N. M., Bathgate, R., … Ye, R. D. (2021). THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors. British Journal of Pharmacology, 178(S1), S27-S156. https://doi.org/10.1111/bph.15538
Alexander, S. P., Fabbro, D., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Southan, C., Davies, J. A., Boison, D., Burns, K. E., Dessauer, C., Gertsch, J., Helsby, N. A., Izzo, A. A., Koesling, D., … Wong, S. S. (2021). THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Enzymes. British Journal of Pharmacology, 178(S1), S313-S411. https://doi.org/10.1111/bph.15542
Alexander, S. P., Mathie, A., Peters, J. A., Veale, E. L., Striessnig, J., Kelly, E., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Southan, C., Davies, J. A., Aldrich, R. W., Attali, B., Baggetta, A. M., Becirovic, E., Biel, M., Bill, R. M., Catterall, W. A., … Zhu, M. (2021). THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Ion channels. British Journal of Pharmacology, 178(S1), S157-S245. https://doi.org/10.1111/bph.15539
Altarifi, A. A., David, B., Muchhala, K. H., Blough, B. E., Akbarali, H., & Negus, S. S. (2017). Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents. Journal of Psychopharmacology, 31, 730-739. https://doi.org/10.1177/0269881116689257
Altier, C., Khosravani, H., Evans, R. M., Hameed, S., Peloquin, J. B., Vartian, B. A., Chen, L., Beedle, A. M., Ferguson, S. S. G., Mezghrani, A., Dubel, S. J., Bourinet, E., McRory, J. E., & Zamponi, G. W. (2006). ORL1 receptor-mediated internalization of N-type calcium channels. Nature Neuroscience, 9, 31-40. https://doi.org/10.1038/nn1605
Ansonoff, M. A., Portoghese, P. S., & Pintar, J. E. (2010). Consequences of opioid receptor mutation on actions of univalent and bivalent kappa and delta ligands. Psychopharmacology, 210, 161-168. https://doi.org/10.1007/s00213-010-1826-7
Arttamangkul, S., Plazek, A., Platt, E. J., Jin, H., Murray, T. F., Birdsong, W. T., Rice, K. C., Farrens, D. L., & Williams, J. T. (2019). Visualizing endogenous opioid receptors in living neurons using ligand-directed chemistry. eLife, 8. e49319. https://doi.org/10.7554/eLife.49319
Ast, J., Arvaniti, A., Fine, N. H. F., Nasteska, D., Ashford, F. B., Stamataki, Z., Koszegi, Z., Bacon, A., Jones, B. J., Lucey, M. A., Sasaki, S., Brierley, D. I., Hastoy, B., Tomas, A., D'Agostino, G., Reimann, F., Lynn, F. C., Reissaus, C. A., Linnemann, A. K., … Hodson, D. J. (2020). Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics. Nature Communications, 11, 467-484. https://doi.org/10.1038/s41467-020-14309-w
Bair, M. J., Robinson, R. L., Katon, W., & Kroenke, K. (2003). Depression and pain comorbidity: A literature review. Archives of Internal Medicine, 163, 2433-2445. https://doi.org/10.1001/archinte.163.20.2433
Barreto, C. A. V., Baptista, S. J., Preto, A. J., Matos-Filipe, P., Mourao, J., Melo, R., & Moreira, I. (2020). Prediction and targeting of GPCR oligomer interfaces. Progress in Molecular Biology and Translational Science, 169, 105-149. https://doi.org/10.1016/bs.pmbts.2019.11.007
Berg, K. A., Rowan, M. P., Gupta, A., Sanchez, T. A., Silva, M., Gomes, I., McGuire, B. A., Portoghese, P. S., Hargreaves, K. M., Devi, L. A., & Clarke, W. P. (2012). Allosteric interactions between delta and kappa opioid receptors in peripheral sensory neurons. Molecular Pharmacology, 81, 264-272. https://doi.org/10.1124/mol.111.072702
Berthoud, H. R., & Neuhuber, W. L. (2000). Functional and chemical anatomy of the afferent vagal system. Autonomic Neuroscience, 85, 1-17. https://doi.org/10.1016/S1566-0702(00)00215-0
Bhushan, R. G., Sharma, S. K., Xie, Z., Daniels, D. J., & Portoghese, P. S. (2004). A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers. Journal of Medicinal Chemistry, 47, 2969-2972. https://doi.org/10.1021/jm0342358
Bohn, L. M., Gainetdinov, R. R., Lin, F. T., Lefkowitz, R. J., & Caron, M. G. (2000). Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature, 408, 720-723. https://doi.org/10.1038/35047086
Breivik, H., Eisenberg, E., & O'Brien, T. (2013). The individual and societal burden of chronic pain in Europe: The case for strategic prioritisation and action to improve knowledge and availability of appropriate care. BMC Public Health, 13, 1229-1241. https://doi.org/10.1186/1471-2458-13-1229
Brouillette, R. L., Besserer-Offroy, E., Mona, C. E., Chartier, M., Lavenus, S., Sousbie, M., Belleville, K., Longpré, J.-M., Marsault, É., Grandbois, M., & Sarret, P. (2020). Cell-penetrating pepducins targeting the neurotensin receptor type 1 relieve pain. Pharmacological Research, 155, 104750. https://doi.org/10.1016/j.phrs.2020.104750
Burbassi, S., Sengupta, R., & Meucci, O. (2010). Alterations of CXCR4 function in mu-opioid receptor-deficient glia. The European Journal of Neuroscience, 32, 1278-1288. https://doi.org/10.1111/j.1460-9568.2010.07402
Bushlin, I., Gupta, A., Stockton, S. D. Jr., Miller, L. K., & Devi, L. A. (2012). Dimerization with cannabinoid receptors allosterically modulates delta opioid receptor activity during neuropathic pain. PLoS ONE, 7, e49789. https://doi.org/10.1371/journal.pone.0049789
Busserolles, J., Lolignier, S., Kerckhove, N., Bertin, C., Authier, N., & Eschalier, A. (2020). Replacement of current opioid drugs focusing on MOR-related strategies. Pharmacology & Therapeutics, 210, 107519. https://doi.org/10.1016/j.pharmthera.2020.107519
Cataldo, G., Erb, S. J., Lunzer, M. M., Luong, N., Akgun, E., Portoghese, P. S., Olson, J. K., & Simone, D. A. (2019). The bivalent ligand MCC22 potently attenuates hyperalgesia in a mouse model of cisplatin-evoked neuropathic pain without tolerance or reward. Neuropharmacology, 158, 107598. https://doi.org/10.1016/j.neuropharm.2019.04.004
Chakrabarti, S., Liu, N. J., & Gintzler, A. R. (2010). Formation of mu−/kappa-opioid receptor heterodimer is sex-dependent and mediates female-specific opioid analgesia. Proceedings of the National Academy of Sciences of the United States of America, 107, 20115-20119. https://doi.org/10.1073/pnas.1009923107
Che, T., English, J., Krumm, B. E., Kim, K., Pardon, E., Olsen, R. H. J., Wang, S., Zhang, S., Diberto, J. F., Sciaky, N., Carroll, F. I., Steyaert, J., Wacker, D., & Roth, B. L. (2020). Nanobody-enabled monitoring of kappa opioid receptor states. Nature Communications, 11, 1145-1156. https://doi.org/10.1038/s41467-020-14889-7
Civciristov, S., Huang, C., Liu, B., Marquez, E. A., Gondin, A. B., Schittenhelm, R. B., Ellisdon, A. M., Canals, M., & Halls, M. L. (2019). Ligand-dependent spatiotemporal signaling profiles of the mu-opioid receptor are controlled by distinct protein-interaction networks. The Journal of Biological Chemistry, 294, 16198-16213. https://doi.org/10.1074/jbc.RA119.008685
Corbett, A. D., Paterson, S. J., & Kosterlitz, H. W. (1993). Selectivity of ligands for opioid receptors. In A. Hertz (Ed.), Opioids I (pp. 645-680). Spinger Verlag.
Daniels, D. J., Kulkarni, A., Xie, Z., Bhushan, R. G., & Portoghese, P. S. (2005). A bivalent ligand (KDAN-18) containing delta-antagonist and kappa-agonist pharmacophores bridges delta2 and kappa1 opioid receptor phenotypes. Journal of Medicinal Chemistry, 48, 1713-1716. https://doi.org/10.1021/jm034234f
Daniels, D. J., Lenard, N. R., Etienne, C. L., Law, P. Y., Roerig, S. C., & Portoghese, P. S. (2005). Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proceedings of the National Academy of Sciences of the United States of America, 102, 19208-19213. https://doi.org/10.1073/pnas.0506627102
Décaillot, F. M., Rozenfeld, R., Gupta, A., & Devi, L. A. (2008). Cell surface targeting of mu-delta opioid receptor heterodimers by RTP4. Proceedings of the National Academy of Sciences of the United States of America, 105, 16045-16050. https://doi.org/10.1073/pnas.0804106105
Degrandmaison, J., Abdallah, K., Blais, V., Génier, S., Lalumière, M.-P, Bergeron, F., Cahill, C. M., Boulter, J., Lavoie, C., Parent, J.-L., & Gendron, L. (2020). In vivo mapping of a GPCR interactome using knockin mice. Proc Natl Acad Sci U S A, 117, 13105-13116. https://doi.org/10.1073/pnas.1917906117
Derouiche, L., Pierre, F., Doridot, S., Ory, S., & Massotte, D. (2020). Heteromerization of endogenous mu and Delta opioid receptors induces ligand-selective co-targeting to lysosomes. Molecules, 25, 4493-4506. https://doi.org/10.3390/molecules25194493
DiCello, J. J., Carbone, S. E., Saito, A., Rajasekhar, P., Ceredig, R. A., Pham, V., Valant, C., Christopoulos, A., Veldhuis, N. A., Canals, M., Massotte, D., & Poole, D. P. (2020). Mu and Delta opioid receptors are Coexpressed and functionally interact in the enteric nervous system of the mouse colon. Cellular and Molecular Gastroenterology and Hepatology, 9, 465-483. https://doi.org/10.1016/j.jcmgh.2019.11.006
Dijkman, P. M., Castell, O. K., Goddard, A. D., Munoz-Garcia, J. C., de Graaf, C., Wallace, M. I., & Watts, A. (2018). Dynamic tuneable G protein-coupled receptor monomer-dimer populations. Nature Communications, 9, 1710-1723. https://doi.org/10.1038/s41467-018-03727-6
Dutta, R., Lunzer, M. M., Auger, J. L., Akgun, E., Portoghese, P. S., & Binstadt, B. A. (2018). A bivalent compound targeting CCR5 and the mu opioid receptor treats inflammatory arthritis pain in mice without inducing pharmacologic tolerance. Arthritis Research & Therapy, 20, 154-163. https://doi.org/10.1186/s13075-018-1661-5
Dvoracsko, S., Keresztes, A., Mollica, A., Stefanucci, A., Macedonio, G., Pieretti, S., Zádor, F., Walter, F. R., Deli, M. A., Kékesi, G., Bánki, L., Tuboly, G., Horváth, G., & Tömböly, C. (2019). Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors. European Journal of Medicinal Chemistry, 178, 571-588. https://doi.org/10.1016/j.ejmech.2019.05.037
Eichel, K., & von Zastrow, M. (2018). Subcellular organization of GPCR signaling. Trends in Pharmacological Sciences, 39, 200-208. https://doi.org/10.1016/j.tips.2017.11.009
Erbs, E., Faget, L., Ceredig, R. A., Matifas, A., Vonesch, J. L., Kieffer, B. L., & Massotte, D. (2016). Impact of chronic morphine on delta opioid receptor-expressing neurons in the mouse hippocampus. Neuroscience, 313, 46-56. https://doi.org/10.1016/j.neuroscience.2015.10.022
Erbs, E., Faget, L., Scherrer, G., Matifas, A., Filliol, D., Vonesch, J. L., Koch, M., Kessler, P., Hentsch, D., Birling, M.-C., Koutsourakis, M., Vasseur, L., Veinante, P., Kieffer, B. L., & Massotte, D. (2015). A mu-delta opioid receptor brain atlas reveals neuronal co-occurrence in subcortical networks. Brain Structure & Function, 220, 677-702. https://doi.org/10.1007/s00429-014-0717-9
Evans, R. M., You, H., Hameed, S., Altier, C., Mezghrani, A., Bourinet, E., & Zamponi, G. W. (2010). Heterodimerization of ORL1 and opioid receptors and its consequences for N-type calcium channel regulation. The Journal of Biological Chemistry, 285, 1032-1040. https://doi.org/10.1074/jbc.M109.040634
Fan, T., Varghese, G., Nguyen, T., Tse, R., O'Dowd, B. F., & George, S. R. (2005). A role for the distal carboxyl tails in generating the novel pharmacology and G protein activation profile of mu and delta opioid receptor hetero-oligomers. The Journal of Biological Chemistry, 280, 38478-38488. https://doi.org/10.1074/jbc.M505644200
Faouzi, A., Uprety, R., Gomes, I., Massaly, N., Keresztes, A. I., Le Rouzic, V., Gupta, A., Zhang, T., Yoon, H. J., Ansonoff, M., Allaoa, A., Pan, Y. X., Pintar, J., Morón, J. A., Streicher, J. M., Devi, L. A., & Majumdar, S. (2020). Synthesis and pharmacology of a novel mu-delta opioid receptor Heteromer-selective agonist based on the Carfentanyl template. Journal of Medicinal Chemistry, 63(22), 13618-13637. https://doi.org/10.1021/acs.jmedchem.0c00901
Filliol, D., Ghozland, S., Chluba, J., Martin, M., Matthes, H. W., Simonin, F., Befort, K., Gavériaux-Ruff, C., Dierich, A., LeMeur, M., Valverde, O., Maldonado, R., & Kieffer, B. L. (2000). Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nature Genetics, 25, 195-200. https://doi.org/10.1038/76061
Fujita, W., Gomes, I., & Devi, L. A. (2014). Revolution in GPCR signaling: Opioid receptor heteromers as novel therapeutic targets. British Journal of Pharmacology, 171, 4155-4176. https://doi.org/10.1111/bph.12798
Fujita, W., Gomes, I., Dove, L. S., Prohaska, D., McIntyre, G., & Devi, L. A. (2014). Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers. Biochemical Pharmacology, 92, 448-456. https://doi.org/10.1016/j.bcp.2014.09.015
Fujita, W., Yokote, M., Gomes, I., Gupta, A., Ueda, H., & Devi, L. A. (2019). Regulation of an opioid receptor chaperone protein, RTP4, by Morphine. Molecular Pharmacology, 95, 11-19. https://doi.org/10.1124/mol.118.112987
Garcia-Recio, A., Navarro, G., Franco, R., Olivella, M., Guixa-Gonzalez, R., & Cordomi, A. (2020). DIMERBOW: Exploring possible GPCR dimer interfaces. Bioinformatics, 36, 3271-3272. https://doi.org/10.1093/bioinformatics/btaa117
Gendron, L., Mittal, N., Beaudry, H., & Walwyn, W. (2015). Recent advances on the delta opioid receptor: From trafficking to function. British Journal of Pharmacology, 172, 403-419. https://doi.org/10.1111/bph.12706
Gillis, A., Kliewer, A., Kelly, E., Henderson, G., Christie, M. J., Schulz, S., & Canals, M. (2020). Critical assessment of G protein-biased Agonism at the mu-opioid receptor. Trends in Pharmacological Sciences, 41, 947-959. https://doi.org/10.1016/j.tips.2020.09.009
Gomes, I., Fujita, W., Gupta, A., Saldanha, S. A., Negri, A., Pinello, C. E., Eberhart, C., Roberts, E., Filizola, M., Hodder, P., & Devi, L. A. (2013). Identification of a mu-delta opioid receptor heteromer-biased agonist with antinociceptive activity. Proceedings of the National Academy of Sciences of the United States of America, 110, 12072-12077. https://doi.org/10.1073/pnas.1222044110
Gomes, I., Gupta, A., Filipovska, J., Szeto, H. H., Pintar, J. E., & Devi, L. A. (2004). A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proceedings of the National Academy of Sciences of the United States of America, 101, 5135-5139. https://doi.org/10.1073/pnas.0307601101
Gomes, I., Ijzerman, A. P., Ye, K., Maillet, E. L., & Devi, L. A. (2011). G protein-coupled receptor heteromerization: A role in allosteric modulation of ligand binding. Molecular Pharmacology, 79, 1044-1052. https://doi.org/10.1124/mol.110.070847
Gomes, I., Jordan, B. A., Gupta, A., Trapaidze, N., Nagy, V., & Devi, L. A. (2000). Heterodimerization of mu and delta opioid receptors: A role in opiate synergy. Journal of Neuroscience, 20, 1-5. https://doi.org/10.1523/JNEUROSCI.20-22-j0007.2000
Gormal, R. S., Padmanabhan, P., Kasula, R., Bademosi, A. T., Coakley, S., Giacomotto, J., Blum, A., Joensuu, M., Wallis, T. P., Lo, H. P., Budnar, S., Rae, J., Ferguson, C., Bastiani, M., Thomas, W. G., Pardon, E., Steyaert, J., Yap, A. S., Goodhill, G. J., … Meunier, F. A. (2020). Modular transient nanoclustering of activated beta2-adrenergic receptors revealed by single-molecule tracking of conformation-specific nanobodies. Proceedings of the National Academy of Sciences of the United States of America, 117, 30476-30487. https://doi.org/10.1073/pnas.2007443117
Grimm, M. C., Ben-Baruch, A., Taub, D. D., Howard, O. M., Resau, J. H., Wang, J. M., Ali, H., Richardson, R., Snyderman, R., & Oppenheim, J. J. (1998). Opiates transdeactivate chemokine receptors: Delta and mu opiate receptor-mediated heterologous desensitization. The Journal of Experimental Medicine, 188, 317-325. https://doi.org/10.1084/jem.188.2.317
Gunther, T., Dasgupta, P., Mann, A., Miess, E., Kliewer, A., Fritzwanker, S., Steinborn, R., & Schulz, S. (2018). Targeting multiple opioid receptors - improved analgesics with reduced side effects? British Journal of Pharmacology, 175, 2857-2868. https://doi.org/10.1111/bph.13809
Gupta, A., Mulder, J., Gomes, I., Rozenfeld, R., Bushlin, I., Ong, E., Lim, M., Maillet, E., Junek, M., Cahill, C. M., Harkany, T., & Devi, L. A. (2010). Increased abundance of opioid receptor heteromers after chronic morphine administration. Science Signaling, 3, ra54. https://doi.org/10.1126/scisignal.2000807
Harvey, J. H., Long, D. H., England, P. M., & Whistler, J. L. (2012). Tuned-affinity bivalent ligands for the characterization of opioid receptor heteromers. ACS Medicinal Chemistry Letters, 3, 640-644. https://doi.org/10.1021/ml300083p
Hasbi, A., Nguyen, T., Fan, T., Cheng, R., Rashid, A., Alijaniaram, M., Rasenick, M. M., O'Dowd, B. F., & George, S. R. (2007). Trafficking of preassembled opioid mu-delta heterooligomer-Gz signaling complexes to the plasma membrane: Coregulation by agonists. Biochemistry, 46, 12997-13009. https://doi.org/10.1021/bi701436w
He, S. Q., Zhang, Z. N., Guan, J. S., Liu, H. R., Zhao, B., Wang, H. B., Li, Q., Yang, H., Luo, J., Li, Z. Y., Wang, Q., Lu, Y. J., Bao, L., & Zhang, X. (2011). Facilitation of mu-opioid receptor activity by preventing delta-opioid receptor-mediated codegradation. Neuron, 69, 120-131. https://doi.org/10.1016/j.neuron.2010.12.001
Heinisch, S., Palma, J., & Kirby, L. G. (2011). Interactions between chemokine and mu-opioid receptors: Anatomical findings and electrophysiological studies in the rat periaqueductal grey. Brain, Behavior, and Immunity, 25, 360-372. https://doi.org/10.1016/j.bbi.2010.10.020
Illes, P., & Norenberg, W. (1990). Blockade of alpha 2-adrenoceptors increases opioid mu-receptor-mediated inhibition of the firing rate of rat locus coeruleus neurones. Naunyn-Schmiedeberg's Archives of Pharmacology, 342, 490-496. https://doi.org/10.1007/BF00169034
Inyang, K. E., George, S. R., & Laumet, G. (2021). The micro-delta opioid heteromer masks latent pain sensitization in neuropathic and inflammatory pain in male and female mice. Brain Research, 1756, 147298. https://doi.org/10.1016/j.brainres.2021.147298
Jacobs, B. A., Pando, M. M., Jennings, E., Chavera, T. A., Clarke, W. P., & Berg, K. A. (2018). Allosterism within delta opioid-kappa opioid receptor Heteromers in peripheral sensory neurons: Regulation of kappa opioid agonist efficacy. Molecular Pharmacology, 93, 376-386. https://doi.org/10.1124/mol.117.109975
Jacobs, B. A., Pando, M. M., Jennings, E. M., Jamshidi, R. J., Zamora, J. C., Chavera, T. S., Clarke, W. P., & Berg, K. A. (2019). Signaling characteristics and functional regulation of delta opioid-kappa opioid receptor (DOP-KOP) heteromers in peripheral sensory neurons. Neuropharmacology, 151, 208-218. https://doi.org/10.1016/j.neuropharm.2019.02.019
Jonas, K. C., Fanelli, F., Huhtaniemi, I. T., & Hanyaloglu, A. C. (2015). Single molecule analysis of functionally asymmetric G protein-coupled receptor (GPCR) oligomers reveals diverse spatial and structural assemblies. The Journal of Biological Chemistry, 290, 3875-3892. https://doi.org/10.1074/jbc.M114.622498
Jorand, R., Biswas, S., Wakefield, D. L., Tobin, S. J., Golfetto, O., Hilton, K., Ko, M., Ramos, J. W., Small, A. R., Chu, P., Singh, G., & Jovanovic-Talisman, T. (2016). Molecular signatures of mu opioid receptor and somatostatin receptor 2 in pancreatic cancer. Molecular Biology of the Cell, 27, 3659-3672. https://doi.org/10.1091/mbc.e16-06-0427
Jordan, B. A., & Devi, L. A. (1999). G-protein-coupled receptor heterodimerization modulates receptor function. Nature, 399, 697-700. https://doi.org/10.1038/21441
Jordan, B. A., Gomes, I., Rios, C., Filipovska, J., & Devi, L. A. (2003). Functional interactions between mu opioid and alpha 2A-adrenergic receptors. Molecular Pharmacology, 64, 1317-1324. https://doi.org/10.1124/mol.64.6.1317
Juhasz, J. R., Hasbi, A., Rashid, A. J., So, C. H., George, S. R., & O'Dowd, B. F. (2008). Mu-opioid receptor heterooligomer formation with the dopamine D1 receptor as directly visualized in living cells. European Journal of Pharmacology, 581, 235-243. https://doi.org/10.1016/j.ejphar.2007.11.060
Kabli, N., Nguyen, T., Balboni, G., O'Dowd, B. F., & George, S. R. (2013). Antidepressant-like and anxiolytic-like effects following activation of the mu-delta opioid receptor heteromer in the nucleus accumbens. Molecular Psychiatry, 19, 968-994. https://doi.org/10.1038/mp.2013.115
Kamp, M. A., Hanggi, D., Steiger, H. J., & Schneider, T. (2012). Diversity of presynaptic calcium channels displaying different synaptic properties. Reviews in the Neurosciences, 23, 179-190. https://doi.org/10.1515/revneuro-2011-0070
Kantas, B., Borzsei, R., Szoke, E., Banhegyi, P., Horvath, A., Hunyady, A., Borbély, É., Hetényi, C., Pintér, E., & Helyes, Z. (2019). Novel drug-like somatostatin receptor 4 agonists are potential analgesics for neuropathic pain. International Journal of Molecular Sciences, 20, 6245-6261. https://doi.org/10.3390/ijms20246245
Kathmann, M., Flau, K., Redmer, A., Trankle, C., & Schlicker, E. (2006). Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 372, 354-361. https://doi.org/10.1007/s00210-006-0033-x
Kharmate, G., Rajput, P. S., Lin, Y. C., & Kumar, U. (2013). Inhibition of tumor promoting signals by activation of SSTR2 and opioid receptors in human breast cancer cells. Cancer Cell International, 13, 93-105. https://doi.org/10.1186/1475-2867-13-93
Kiguchi, N., Ding, H., Kishioka, S., & Ko, M. C. (2020). Nociceptin/Orphanin FQ peptide receptor-related ligands as novel analgesics. Current Topics in Medicinal Chemistry, 20, 2878-2888. https://doi.org/10.2174/1568026620666200508082615
Kliewer, A., Schmiedel, F., Sianati, S., Bailey, A., Bateman, J. T., Levitt, E. S., Williams, J. T., Christie, M. J., & Schulz, S. (2019). Phosphorylation-deficient G-protein-biased mu-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects. Nature Communications, 10, 367-377. https://doi.org/10.1038/s41467-018-08162-1
Koshimizu, T. A., Honda, K., Nagaoka-Uozumi, S., Ichimura, A., Kimura, I., Nakaya, M., Sakai, N., Shibata, K., Ushijima, K., Fujimura, A., Hirasawa, A., Kurose, H., Tsujimoto, G., Tanoue, A., & Takano, Y. (2018). Complex formation between the vasopressin 1b receptor, beta-arrestin-2, and the mu-opioid receptor underlies morphine tolerance. Nature Neuroscience, 21, 820-833. https://doi.org/10.1038/s41593-018-0144-y
Kremer, M., Salvat, E., Muller, A., Yalcin, I., & Barrot, M. (2016). Antidepressants and gabapentinoids in neuropathic pain: Mechanistic insights. Neuroscience, 338, 183-206. https://doi.org/10.1016/j.neuroscience.2016.06.057
Lambert, G. A., & Zagami, A. S. (2018). Does somatostatin have a role to play in migraine headache? Neuropeptides, 69, 1-8. https://doi.org/10.1016/j.npep.2018.04.006
Law, P. Y., Erickson-Herbrandson, L. J., Zha, Q. Q., Solberg, J., Chu, J., Sarre, A., & Loh, H. H. (2005). Heterodimerization of mu- and delta-opioid receptors occurs at the cell surface only and requires receptor-G protein interactions. The Journal of Biological Chemistry, 280, 11152-11164. https://doi.org/10.1074/jbc.M500171200
Le Naour, M., Akgun, E., Yekkirala, A., Lunzer, M. M., Powers, M. D., Kalyuzhny, A. E., & Portoghese, P. S. (2013). Bivalent ligands that target mu opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance. Journal of Medicinal Chemistry, 56, 5505-5513. https://doi.org/10.1021/jm4005219
Lee, Y. K., Choi, D. Y., Jung, Y. Y., Yun, Y. W., Lee, B. J., Han, S. B., & Hong, J. T. (2013). Decreased pain responses of C-C chemokine receptor 5 knockout mice to chemical or inflammatory stimuli. Neuropharmacology, 67, 57-65. https://doi.org/10.1016/j.neuropharm.2012.10.030
Lei, W., Vekariya, R. H., Ananthan, S., & Streicher, J. M. (2020). A novel Mu-Delta opioid agonist demonstrates enhanced efficacy with reduced tolerance and dependence in mouse neuropathic pain models. The Journal of Pain, 21, 146-160. https://doi.org/10.1016/j.jpain.2019.05.017
Lenard, N. R., Daniels, D. J., Portoghese, P. S., & Roerig, S. C. (2007). Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores. European Journal of Pharmacology, 566, 75-82. https://doi.org/10.1016/j.ejphar.2007.02.040
Liu, H., Tian, Y., Ji, B., Lu, H., Xin, Q., Jiang, Y., Ding, L., Zhang, J., Chen, J., & Bai, B. (2016). Heterodimerization of the kappa opioid receptor and neurotensin receptor 1 contributes to a novel beta-arrestin-2-biased pathway. Biochimica et Biophysica Acta, 1863, 2719-2738. https://doi.org/10.1016/j.bbamcr.2016.07.009
Liu, N. J., Chakrabarti, S., Schnell, S., Wessendorf, M., & Gintzler, A. R. (2011). Spinal synthesis of estrogen and concomitant signaling by membrane estrogen receptors regulate spinal kappa- and mu-opioid receptor heterodimerization and female-specific spinal morphine antinociception. The Journal of Neuroscience, 31, 11836-11845. https://doi.org/10.1523/JNEUROSCI.1901-11.2011
Liu, N. J., von Gizycki, H., & Gintzler, A. R. (2007). Sexually dimorphic recruitment of spinal opioid analgesic pathways by the spinal application of morphine. The Journal of Pharmacology and Experimental Therapeutics, 322, 654-660. https://doi.org/10.1124/jpet.107.123620
Liu, X. Y., Liu, Z. C., Sun, Y. G., Ross, M., Kim, S., Tsai, F. F., Li, Q.-F., Jeffry, J., Kim, J.-Y., Loh, H. H., & Chen, Z.-F. (2011). Unidirectional cross-activation of GRPR by MOR1D uncouples itch and analgesia induced by opioids. Cell, 147, 447-458. https://doi.org/10.1016/j.cell.2011.08.043
Livingston, K. E., Mahoney, J. P., Manglik, A., Sunahara, R. K., & Traynor, J. R. (2018). Measuring ligand efficacy at the mu-opioid receptor using a conformational biosensor. eLife, 7, e32499. https://doi.org/10.7554/eLife.32499
Machelska, H., & Celik, M. O. (2018). Advances in achieving opioid analgesia without side effects. Frontiers in Pharmacology, 9, 1388. https://doi.org/10.3389/fphar.2018.01388
Manduca, A., Lassalle, O., Sepers, M., Campolongo, P., Cuomo, V., Marsicano, G., Kieffer, B., Vanderschuren, L. J., Trezza, V., & Manzoni, O. J. (2016). Interacting cannabinoid and opioid receptors in the nucleus Accumbens Core control adolescent social play. Frontiers in Behavioral Neuroscience, 10, 211. https://doi.org/10.3389/fnbeh.2016.00211
Manglik, A., Kruse, A. C., Kobilka, T. S., Thian, F. S., Mathiesen, J. M., Sunahara, R. K., Pardo, L., Weis, W. I., Kobilka, B. K., & Granier, S. (2012). Crystal structure of the micro-opioid receptor bound to a morphinan antagonist. Nature, 485, 321-326. https://doi.org/10.1038/nature10954
Margolis, E. B., Fujita, W., Devi, L. A., & Fields, H. L. (2017). Two delta opioid receptor subtypes are functional in single ventral tegmental area neurons, and can interact with the mu opioid receptor. Neuropharmacology, 123, 420-432. https://doi.org/10.1016/j.neuropharm.2017.06.019
Massotte, D. (2015). In vivo opioid receptor heteromerization: Where do we stand? British Journal of Pharmacology, 172, 420-434. https://doi.org/10.1111/bph.12702
Mathews, J. L., Fulton, B. S., Negus, S. S., Neumeyer, J. L., & Bidlack, J. M. (2008). In vivo characterization of (−)(−)MCL-144 and (+)(−)MCL-193: Isomeric, bivalent ligands with mu/kappa agonist properties. Neurochemical Research, 33, 2142-2150. https://doi.org/10.1007/s11064-008-9752-3
Matthes, H. W., Maldonado, R., Simonin, F., Valverde, O., Slowe, S., Kitchen, I., Befort, K., Dierich, A., Le Meur, M., Dollé, P., Tzavara, E., Hanoune, J., Roques, B. P., & Kieffer, B. L. (1996). Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature, 383, 819-823. https://doi.org/10.1038/383819a0
Menon, S., Lea, R. A., Roy, B., Hanna, M., Wee, S., Haupt, L. M., & Griffiths, L. R. (2012). The human mu-opioid receptor gene polymorphism (A118G) is associated with head pain severity in a clinical cohort of female migraine with aura patients. The Journal of Headache and Pain, 13, 513-519. https://doi.org/10.1007/s10194-012-0468-z
Mitronova, G. Y., Lukinavicius, G., Butkevich, A. N., Kohl, T., Belov, V. N., Lehnart, S. E., & Hell, S. W. (2017). High-affinity functional fluorescent ligands for human beta-adrenoceptors. Scientific Reports, 7, 12319-12333. https://doi.org/10.1038/s41598-017-12468-3
Moller, J., Isbilir, A., Sungkaworn, T., Osberg, B., Karathanasis, C., Sunkara, V., Grushevskyi, E. O., Bock, A., Annibale, P., Heilemann, M., Schütte, C., & Lohse, M. J. (2020). Single-molecule analysis reveals agonist-specific dimer formation of micro-opioid receptors. Nature Chemical Biology, 16, 946-954. https://doi.org/10.1038/s41589-020-0566-1
Moller, T. C., Hottin, J., Clerte, C., Zwier, J. M., Durroux, T., Rondard, P., Prézeau, L., Royer, C. A., Pin, J.-P., Margeat, E., & Kniazeff, J. (2018). Oligomerization of a G protein-coupled receptor in neurons controlled by its structural dynamics. Scientific Reports, 8, 10414-10428. https://doi.org/10.1038/s41598-018-28682-6
Moreno, E., Quiroz, C., Rea, W., Cai, N. S., Mallol, J., Cortes, A., Lluís, C., Canela, E. I., Casadó, V., & Ferré, S. (2017). Functional mu-opioid-Galanin receptor Heteromers in the ventral tegmental area. The Journal of Neuroscience, 37, 1176-1186. https://doi.org/10.1523/JNEUROSCI.2442-16.2016
Morgan, M. M., Peecher, D. L., & Streicher, J. M. (2021). Use of home cage wheel running to assess the behavioural effects of administering a mu/delta opioid receptor heterodimer antagonist for spontaneous morphine withdrawal in the rat. Behavioural Brain Research, 397, 112953. https://doi.org/10.1016/j.bbr.2020.112953
Nadal, X., La Porta, C., Andreea Bura, S., & Maldonado, R. (2013). Involvement of the opioid and cannabinoid systems in pain control: New insights from knockout studies. European Journal of Pharmacology, 716, 142-157. https://doi.org/10.1016/j.ejphar.2013.01.077
O'Dowd, B. F., Ji, X., O'Dowd, P. B., Nguyen, T., & George, S. R. (2012). Disruption of the mu-delta opioid receptor heteromer. Biochemical and Biophysical Research Communications, 422, 556-560. https://doi.org/10.1016/j.bbrc.2012.05.023
Olson, K. M., Keresztes, A., Tashiro, J. K., Daconta, L. V., Hruby, V. J., & Streicher, J. M. (2018). Synthesis and evaluation of a novel bivalent selective antagonist for the Mu-Delta opioid receptor heterodimer that reduces Morphine withdrawal in mice. Journal of Medicinal Chemistry, 61, 6075-6086. https://doi.org/10.1021/acs.jmedchem.8b00403
Ozawa, A., Brunori, G., Mercatelli, D., Wu, J., Cippitelli, A., Zou, B., Xie, X. S., Williams, M., Zaveri, N. T., Low, S., Scherrer, G., Kieffer, B. L., & Toll, L. (2015). Knock-in mice with NOP-eGFP receptors identify receptor cellular and regional localization. The Journal of Neuroscience, 35, 11682-11693. https://doi.org/10.1523/JNEUROSCI.5122-14.2015
Pei, L., Lee, F. J., Moszczynska, A., Vukusic, B., & Liu, F. (2004). Regulation of dopamine D1 receptor function by physical interaction with the NMDA receptors. The Journal of Neuroscience, 24, 1149-1158. https://doi.org/10.1523/JNEUROSCI.3922-03.2004
Pello, O. M., Martinez-Munoz, L., Parrillas, V., Serrano, A., Rodriguez-Frade, J. M., Toro, M. J., Lucas, P., Monterrubio, M., Martínez-A, C., & Mellado, M. (2008). Ligand stabilization of CXCR4/delta-opioid receptor heterodimers reveals a mechanism for immune response regulation. European Journal of Immunology, 38, 537-549. https://doi.org/10.1002/eji.200737630
Pierre, F., Ugur, M., Faivre, F., Doridot, S., Veinante, P., & Massotte, D. (2019). Morphine-dependent and abstinent mice are characterized by a broader distribution of the neurons co-expressing mu and delta opioid receptors. Neuropharmacology, 152, 30-41. https://doi.org/10.1016/j.neuropharm.2019.03.009
Prangsma, J. C., Molenaar, R., van Weeren, L., Bindels, D. S., Haarbosch, L., Stouthamer, J., Gadella, T. W. J. Jr., Subramaniam, V., Vos, W. L., & Blum, C. (2020). Quantitative determination of dark chromophore population explains the apparent Low quantum yield of red fluorescent proteins. The Journal of Physical Chemistry. B, 124, 1383-1391. https://doi.org/10.1021/acs.jpcb.9b10396
Provasi, D., Boz, M. B., Johnston, J. M., & Filizola, M. (2015). Preferred supramolecular organization and dimer interfaces of opioid receptors from simulated self-association. PLoS Computational Biology, 11, e1004148. https://doi.org/10.1371/journal.pcbi.1004148
Raehal, K. M., Walker, J. K., & Bohn, L. M. (2005). Morphine side effects in beta-arrestin 2 knockout mice. The Journal of Pharmacology and Experimental Therapeutics, 314, 1195-1201. https://doi.org/10.1124/jpet.105.087254
Raja, S. N., Carr, D. B., Cohen, M., Finnerup, N. B., Flor, H., Gibson, S., Keefe, F. J., Mogil, J. S., Ringkamp, M., Sluka, K. A., Song, X. J., Stevens, B., Sullivan, M. D., Tutelman, P. R., Ushida, T., & Vader, K. (2020). The revised International Association for the Study of Pain definition of pain: Concepts, challenges, and compromises. Pain, 161, 1976-1982. https://doi.org/10.1097/j.pain.0000000000001939
Rios, C., Gomes, I., & Devi, L. A. (2006). Mu opioid and CB1 cannabinoid receptor interactions: Reciprocal inhibition of receptor signaling and neuritogenesis. British Journal of Pharmacology, 148, 387-395. https://doi.org/10.1038/sj.bjp.0706757
Rives, M. L., Rossillo, M., Liu-Chen, L. Y., & Javitch, J. A. (2012). 6′-Guanidinonaltrindole (6'-GNTI) is a G protein-biased kappa-opioid receptor agonist that inhibits arrestin recruitment. The Journal of Biological Chemistry, 287, 27050-27054. https://doi.org/10.1074/jbc.C112.387332
Rodriguez, J. J., Mackie, K., & Pickel, V. M. (2001). Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat caudate putamen nucleus. The Journal of Neuroscience, 21, 823-833. https://doi.org/10.1523/JNEUROSCI.21-03-00823.2001
Rodriguez-Munoz, M., Sanchez-Blazquez, P., Vicente-Sanchez, A., Berrocoso, E., & Garzon, J. (2012). The mu-opioid receptor and the NMDA receptor associate in PAG neurons: Implications in pain control. Neuropsychopharmacology, 37, 338-349. https://doi.org/10.1038/npp.2011.155
Rozenfeld, R., Bushlin, I., Gomes, I., Tzavaras, N., Gupta, A., Neves, S., Battini, L., Gusella, G. L., Lachmann, A., Ma'ayan, A., Blitzer, R. D., & Devi, L. A. (2012). Receptor heteromerization expands the repertoire of cannabinoid signaling in rodent neurons. PLoS ONE, 7, e29239. https://doi.org/10.1371/journal.pone.0029239
Rozenfeld, R., & Devi, L. A. (2007). Receptor heterodimerization leads to a switch in signaling: Beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers. The FASEB Journal, 21, 2455-2465. https://doi.org/10.1096/fj.06-7793com
Sacco, M., Meschi, M., Regolisti, G., Detrenis, S., Bianchi, L., Bertorelli, M., Pioli, S., Magnano, A., Spagnoli, F., Giuri, P. G., Fiaccadori, E., & Caiazza, A. (2013). The relationship between blood pressure and pain. Journal of Clinical Hypertension (Greenwich, Conn.), 15, 600-605. https://doi.org/10.1111/jch.12145
Schmid, C. L., Streicher, J. M., Groer, C. E., Munro, T. A., Zhou, L., & Bohn, L. M. (2013). Functional selectivity of 6′-guanidinonaltrindole (6'-GNTI) at kappa-opioid receptors in striatal neurons. The Journal of Biological Chemistry, 288, 22387-22398. https://doi.org/10.1074/jbc.M113.476234
Sierra, S., Gupta, A., Gomes, I., Fowkes, M., Ram, A., Bobeck, E. N., & Devi, L. A. (2019). Targeting cannabinoid 1 and Delta opioid receptor Heteromers alleviates chemotherapy-induced neuropathic pain. ACS Pharmacology & Translational Science, 2, 219-229. https://doi.org/10.1021/acsptsci.9b00008
Singleton, S., Baptista-Hon, D. T., Edelsten, E., McCaughey, K. S., Camplisson, E., & Hales, T. G. (2021). TRV130 partial agonism and capacity to induce anti-nociceptive tolerance revealed through reducing available mu-opioid receptor number. British Journal of Pharmacology, 178, 1855-1868. https://doi.org/10.1111/bph.15409
Somvanshi, R. K., & Kumar, U. (2014). Delta-opioid receptor and somatostatin receptor-4 heterodimerization: Possible implications in modulation of pain associated signaling. PLoS ONE, 9, e85193. https://doi.org/10.1371/journal.pone.0085193
Song, C., Rahim, R. T., Davey, P. C., Bednar, F., Bardi, G., Zhang, L., Zhang, N., Oppenheim, J. J., & Rogers, T. J. (2011). Protein kinase Czeta mediates micro-opioid receptor-induced cross-desensitization of chemokine receptor CCR5. The Journal of Biological Chemistry, 286, 20354-20365. https://doi.org/10.1074/jbc.M110.177303
Stoneman, M. R., Biener, G., Ward, R. J., Pediani, J. D., Badu, D., Eis, A., Popa, I., Milligan, G., & Raicu, V. (2019). A general method to quantify ligand-driven oligomerization from fluorescence-based images. Nature Methods, 16, 493-496. https://doi.org/10.1038/s41592-019-0408-9
Sun, G. C., Ho, W. Y., Chen, B. R., Cheng, P. W., Cheng, W. H., Hsu, M. C., Yeh, T. C., Hsiao, M., Lu, P. J., & Tseng, C. J. (2015). GPCR dimerization in brainstem nuclei contributes to the development of hypertension. British Journal of Pharmacology, 172, 2507-2518. https://doi.org/10.1111/bph.13074
Sun, G. C., Wong, T. Y., Chen, H. H., Ho, C. Y., Yeh, T. C., Ho, W. Y., Tseng, C. J., & Cheng, P. W. (2019). Angiotensin II inhibits DDAH1-nNOS signaling via AT1R and muOR dimerization to modulate blood pressure control in the central nervous system. Clinical Science (London, England), 133, 2401-2413. https://doi.org/10.1042/CS20191005
Sungkaworn, T., Jobin, M. L., Burnecki, K., Weron, A., Lohse, M. J., & Calebiro, D. (2017). Single-molecule imaging reveals receptor-G protein interactions at cell surface hot spots. Nature, 550, 543-547. https://doi.org/10.1038/nature24264
Suzuki, S., Chuang, L. F., Yau, P., Doi, R. H., & Chuang, R. Y. (2002). Interactions of opioid and chemokine receptors: Oligomerization of mu, kappa, and delta with CCR5 on immune cells. Experimental Cell Research, 280, 192-200. https://doi.org/10.1006/excr.2002.5638
Sykes, K. T., White, S. R., Hurley, R. W., Mizoguchi, H., Tseng, L. F., & Hammond, D. L. (2007). Mechanisms responsible for the enhanced antinociceptive effects of micro-opioid receptor agonists in the rostral ventromedial medulla of male rats with persistent inflammatory pain. The Journal of Pharmacology and Experimental Therapeutics, 322, 813-821. https://doi.org/10.1124/jpet.107.121954
Szabo, I., Chen, X. H., Xin, L., Adler, M. W., Howard, O. M., Oppenheim, J. J., & Rogers, T. J. (2002). Heterologous desensitization of opioid receptors by chemokines inhibits chemotaxis and enhances the perception of pain. Proceedings of the National Academy of Sciences of the United States of America, 99, 10276-10281. https://doi.org/10.1073/pnas.102327699
Tan, M., Walwyn, W. M., Evans, C. J., & Xie, C. W. (2009). p38 MAPK and beta-arrestin 2 mediate functional interactions between endogenous micro-opioid and alpha2A-adrenergic receptors in neurons. The Journal of Biological Chemistry, 284, 6270-6281. https://doi.org/10.1074/jbc.M806742200
Tao, Y. M., Yu, C., Wang, W. S., Hou, Y. Y., Xu, X. J., Chi, Z. Q., Ding, Y. Q., Wang, Y. J., & Liu, J. G. (2017). Heteromers of mu opioid and dopamine D1 receptors modulate opioid-induced locomotor sensitization in a dopamine-independent manner. British Journal of Pharmacology, 174, 2842-2861. https://doi.org/10.1111/bph.13908
Tiwari, V., He, S. Q., Huang, Q., Liang, L., Yang, F., Chen, Z., Tiwari, V., Fujita, W., Devi, L. A., Dong, X., Guan, Y., & Raja, S. N. (2020). Activation of micro-delta opioid receptor heteromers inhibits neuropathic pain behavior in rodents. Pain, 161, 842-855. https://doi.org/10.1097/j.pain.0000000000001768
Toll, L., Berzetei-Gurske, I. P., Polgar, W. E., Brandt, S. R., Adapa, I. D., Rodriguez, L., Schwartz, R. W., Haggart, D., O'Brien, A., White, A., Kennedy, J. M., Craymer, K., Farrington, L., & Auh, J. S. (1998). Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Research Monograph, 178, 440-466.
Treede, R. D., Rief, W., Barke, A., Aziz, Q., Bennett, M. I., Benoliel, R., Cohen, M., Evers, S., Finnerup, N. B., First, M. B., Giamberardino, M. A., Kaasa, S., Korwisi, B., Kosek, E., Lavand'homme, P., Nicholas, M., Perrot, S., Scholz, J., Schug, S., … Wang, S. J. (2019). Chronic pain as a symptom or a disease: The IASP classification of chronic pain for the international classification of diseases (ICD-11). Pain, 160, 19-27. https://doi.org/10.1097/j.pain.0000000000001384
Ugur, M., Derouiche, L., & Massotte, D. (2018). Heteromerization modulates mu opioid receptor functional properties in vivo. Frontiers in Pharmacology, 9, 1240. https://doi.org/10.3389/fphar.2018.01240
van Rijn, R. M., Brissett, D. I., & Whistler, J. L. (2012). Emergence of functional spinal delta opioid receptors after chronic ethanol exposure. Biological Psychiatry, 71, 232-238. https://doi.org/10.1016/j.biopsych.2011.07.015
Vaysse, P. J., Gardner, E. L., & Zukin, R. S. (1987). Modulation of rat brain opioid receptors by cannabinoids. The Journal of Pharmacology and Experimental Therapeutics, 241, 534-539.
Vergura, R., Balboni, G., Spagnolo, B., Gavioli, E., Lambert, D. G., McDonald, J., Trapella, C., Lazarus, L. H., Regoli, D., Guerrini, R., & Salvadori, S. (2008). Anxiolytic- and antidepressant-like activities of H-Dmt-tic-NH-CH (CH2-COOH)-bid (UFP-512), a novel selective delta opioid receptor agonist. Peptides, 29, 93-103. https://doi.org/10.1016/j.peptides.2007.10.012
Wade, P. R., Palmer, J. M., McKenney, S., Kenigs, V., Chevalier, K., Moore, B. A., Mabus, J. R., Saunders, P. R., Wallace, N. H., Schneider, C. R., Kimball, E. S., Breslin, H. J., He, W., & Hornby, P. J. (2012). Modulation of gastrointestinal function by MuDelta, a mixed micro opioid receptor agonist/micro opioid receptor antagonist. British Journal of Pharmacology, 167, 1111-1125. https://doi.org/10.1111/j.1476-5381.2012.02068.x
Waldhoer, M., Fong, J., Jones, R. M., Lunzer, M. M., Sharma, S. K., Kostenis, E., Portoghese, P. S., & Whistler, J. L. (2005). A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proceedings of the National Academy of Sciences of the United States of America, 102, 9050-9055. https://doi.org/10.1073/pnas.0501112102
Walwyn, W., John, S., Maga, M., Evans, C. J., & Hales, T. G. (2009). Delta receptors are required for full inhibitory coupling of mu-receptors to voltage-dependent ca(2+) channels in dorsal root ganglion neurons. Molecular Pharmacology, 76, 134-143. https://doi.org/10.1124/mol.109.055913
Wang, H. L., Hsu, C. Y., Huang, P. C., Kuo, Y. L., Li, A. H., Yeh, T. H., Tso, A. S., & Chen, Y. L. (2005). Heterodimerization of opioid receptor-like 1 and mu-opioid receptors impairs the potency of micro receptor agonist. Journal of Neurochemistry, 92, 1285-1294. https://doi.org/10.1111/j.1471-4159.2004.02921.x
Xie, W. Y., He, Y., Yang, Y. R., Li, Y. F., Kang, K., Xing, B. M., & Wang, Y. (2009). Disruption of Cdk5-associated phosphorylation of residue threonine-161 of the delta-opioid receptor: Impaired receptor function and attenuated morphine antinociceptive tolerance. The Journal of Neuroscience, 29, 3551-3564. https://doi.org/10.1523/JNEUROSCI.0415-09.2009
Yang, Y., Li, Q., He, Q. H., Han, J. S., Su, L., & Wan, Y. (2018). Heteromerization of mu-opioid receptor and cholecystokinin B receptor through the third transmembrane domain of the mu-opioid receptor contributes to the anti-opioid effects of cholecystokinin octapeptide. Experimental & Molecular Medicine, 50, 1-16. https://doi.org/10.1038/s12276-018-0090-5
Yekkirala, A. S., Lunzer, M. M., McCurdy, C. R., Powers, M. D., Kalyuzhny, A. E., Roerig, S. C., & Portoghese, P. S. (2011). N-naphthoyl-beta-naltrexamine (NNTA), a highly selective and potent activator of mu/kappa-opioid heteromers. Proceedings of the National Academy of Sciences of the United States of America, 108, 5098-5103. https://doi.org/10.1073/pnas.1016277108
Yin, A. Q., Wang, F., & Zhang, X. (2019). Integrating endocannabinoid signaling in the regulation of anxiety and depression. Acta Pharmacologica Sinica, 40, 336-341. https://doi.org/10.1038/s41401-018-0051-5
Yoo, J. H., Bailey, A., Borsodi, A., Toth, G., Matifas, A., Kieffer, B. L., & Kitchen, I. (2014). Knockout subtraction autoradiography: A novel ex vivo method to detect heteromers finds sparse KOP receptor/DOP receptor heterodimerization in the brain. European Journal of Pharmacology, 731, 1-7. https://doi.org/10.1016/j.ejphar.2014.03.007
Zhang, Z., & Pan, Z. Z. (2010). Synaptic mechanism for functional synergism between delta- and mu-opioid receptors. The Journal of Neuroscience, 30, 4735-4745. https://doi.org/10.1523/JNEUROSCI.5968-09.2010
Zheng, H., Zou, H., Liu, X., Chu, J., Zhou, Y., Loh, H. H., & Law, P. Y. (2012). Cholesterol level influences opioid signaling in cell models and analgesia in mice and humans. Journal of Lipid Research, 53, 1153-1162. https://doi.org/10.1194/jlr.M024455